Novo Holdings Amends IO Biotech Stake

TL;DR

Novo Holdings updated its IO Biotech filing, watch for ownership changes.

AI Summary

Novo Holdings A/S has amended its Schedule 13D filing for IO Biotech, Inc. on September 17, 2024. The filing indicates a change in beneficial ownership, though specific new holdings or dollar amounts are not detailed in this excerpt. Novo Holdings A/S, previously known as Novo A/S, is based in Hellerup, Denmark.

Why It Matters

This amendment signals a potential shift in the ownership structure or investment strategy of IO Biotech, Inc. by a significant stakeholder.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings can indicate significant changes in a major shareholder's position, potentially impacting stock price and corporate strategy.

Key Players & Entities

• Novo Holdings A/S (company) — Filing entity
• IO Biotech, Inc. (company) — Subject company
• Novo A/S (company) — Former name of Novo Holdings A/S
• Barbara Fiorini (person) — Authorized person to receive notices
• B. Shayne Kennedy (person) — Copy to contact

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $2.47 — of common stock at an exercise price of $2.47 per share. (2) Based upon (i) 65,880
• $0.8313 — ovo Holdings A/S sold 250,000 shares at $0.8313 per share, with prices ranging from $0.
• $0.7911 — 313 per share, with prices ranging from $0.7911 to $0.876, in a block trade. On Septe
• $0 — re, with prices ranging from $0.7911 to $0.876, in a block trade. On September 1
• $0.7744 — ovo Holdings A/S sold 250,000 shares at $0.7744 per share, with prices ranging from $0.
• $0.752 — 744 per share, with prices ranging from $0.752 to $0.83, in a block trade. On Septem
• $0.7513 — ovo Holdings A/S sold 250,000 shares at $0.7513 per share, with prices ranging from $0.
• $0.7327 — 513 per share, with prices ranging from $0.7327 to $0.779, in a block trade. On Septe
• $0.7867 — ovo Holdings A/S sold 250,000 shares at $0.7867 per share, with prices ranging from $0.
• $0.7535 — 867 per share, with prices ranging from $0.7535 to $0.8875, in a block trade. Item5.

Filing Documents

• d794263dsc13da.htm (SC 13D/A) — 32KB
• 0001193125-24-220873.txt ( ) — 34KB

is amended and replaced in its entirety as follows

Item 5 is amended and replaced in its entirety as follows: (a) Novo Holdings A/S beneficially owns 5,823,584 shares of Common Stock (the Novo Shares ) representing approximately 8.5% of the Issuers outstanding shares of Common Stock, based upon (i) 65,880,914 shares of the Issuers Common Stock outstanding as of August 8, 2024, as reported in the Issuers Form 10-Q filed with the SEC on August 13, 2024 plus (ii) 2,469,135 shares of Common Stock issuable upon the exercise of the warrants held by Novo Holdings A/S. (b) Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares. (c) Except as described herein, Novo Holdings A/S has not effected any transactions in the Issuers Common Shares within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuers Common Shares within the past 60 days. (d) Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares. (e) Not applicable. 3 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: September 17, 2024 Novo Holdings A/S /s/ Barbara Fiorini Due By: Barbara Fiorini Due Its: General Counsel, Finance & Operations

View Full Filing

View this SC 13D/A filing on SEC EDGAR